ArticleCureus2025
Clinico-Hematological Profile of Children and Adolescents With Chronic Myeloid Leukemia: A Study at a Tertiary Care Institute in India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Chronic myeloid leukemia in a 13-year-old-a rare pediatric case of extreme hyperleukocytosis in chronic phase.Frontiers in medicine · 2026Article
- Predictors of Response to Imatinib Therapy and Long-Term Outcomes in Paediatric and Adolescent Patients With Chronic Myeloid Leukaemia.Cancer reports (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Chronic myeloid leukemia (CML) rarely occurs in the first few decades of life, accounting for 2% to 3% of leukemias in children and adolescents. Children and adolescents with CML tend to present with more aggressive features. Because of the substantial shift in CML treatment brought about by the development of tyrosine kinase inhibitors (TKIs) in the last 20 years, adult patients now have about the same life expectancy as the age-matched healthy population. The study evaluated the clinico-hematological profile of children presenting with CML. Also, the response to the treatment provided was analyzed. Materials and methods It is a retrospective-observational study conducted in the Department of Hematology, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India. The Institutional Ethics Committee (IEC), IGIMS, Patna, Bihar, India, granted ethical approval under letter 1370/IEC/IGIMS/2024, dated 20 March 2024. Results Out of 180 cases detected from records of the previous six years, i.e., from 2018 to 2023, only 20 records of CML were found in children and adolescents. Among them, 17 (85%) patients had splenomegaly, 16 (80%) had anemia, 10 (50%) had hepatomegaly, and two (10%) had fever. Conclusion The study concluded that the presenting features of CML in children and adolescents were similar to those shown in other studies. WBC counts were higher in children and adolescents compared to the adult population. Also, the long-term outcomes of TKI treatment and the late effects of life-long TKI treatment need to be defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.